Shenlian Bio's Lanzhou branch has been approved to produce a bivalent synthetic peptide vaccine against swine foot-and-mouth disease types O and South Africa 1, and has obtained a temporary veterinary drug product approval number. The product uses a synthetic polypeptide technology platform and complements the company's two previously approved inactivated vaccines containing the South Africa 1 strain, forming a product matrix of South Africa 1 foot-and-mouth disease vaccines covering pigs, cattle, and sheep. Before the product can be marketed and sold, procedures such as batch release still need to be completed. Specific sales will be affected by factors such as epidemic prevention policies and market capacity, and returns are uncertain.
Shanghai Shen Lian Biomedical CorpApproval for new bivalent synthetic peptide vaccine expands product portfolio.
